N-Zyme Biomedical

N-Zyme Biomedical

HealthReflux Disease Treatment📍 Newark, United States

N-Zyme Biomedical is focused on developing novel therapies for reflux disease, specifically through its pepsin inhibitor platform. The company aims to address significant unmet medical needs in conditions like laryngopharyngeal reflux and gastroesophageal reflux disease. This funding round will accelerate their Phase 2 clinical programs and further their innovative approach to treatment.

Total raised
$4.6M
tracked to date
Latest round
Series A
Jul 21, 2026
Known investors
1
led by unknown
Press coverage
3
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $4.6MSeries AJul 21, 2026

    Led by unknown

    Announcement ↗

Founder

Franco Vigile
Franco Vigile
Co-Founder and Chief Executive Officer

Investors in N-Zyme Biomedical

Backers from this company's tracked funding rounds.

N-Zyme Biomedical in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile